Study wrapper · #1105
Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults.
Amioka M, Amioka H, Kinoshita H, et al. Diabetes, obesity & metabolism. 2026.
DOI: 10.1111/dom.71162PubMed: 42521631
Editor's note
This prospective non-randomized cohort compared two low maintenance doses of tirzepatide and found comparable weight loss with better tolerability at 2.5 mg. The non-randomized, shared-decision dosing design introduces potential confounding, so the dose-equivalence signal should be regarded as preliminary.
Plain-language abstract
In non-diabetic Japanese adults with obesity, 2.5 mg and 5 mg maintenance doses of tirzepatide produced similar weight loss (about 15-16%) at 6 months, with fewer side effects at the lower dose. This suggests lower-dose strategies may be useful in practice.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026